Cardiol Therapeutics Inc Class A saw a significant surge, closing up 10.13% in the latest trading session.
In a remarkable turn of events, Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a notable increase in its stock price, closing at CA$1.74. This 10.13% rise signals strong interest from investors, likely driven by recent developments in the company's clinical research.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$192.50M
52W high
$2.33
52W low
$1.23
1W change
-6.29%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 265.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+265.9% Upside
Current Price
C$1.64
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
50.9%
Annualized
90-Day Vol
60.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.55 | C$1.30 – C$1.84 |
| 60 trading days | C$1.46 | C$1.14 – C$1.87 |
| 90 trading days | C$1.37 | C$1.01 – C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The surge in Cardiol's stock price may reflect growing investor confidence in its ongoing clinical trials and the potential for future growth in the cardiovascular treatment market.
Stock Price Climbs 10.13%
With a market cap of CA$182 million, Cardiol Therapeutics' stock price increase shows a growing market interest in innovative cardiovascular therapies.
Bull case
Investors are feeling optimistic about Cardiol Therapeutics' recent Phase II study results, published in a respected medical journal. These results highlight the effectiveness of their treatment for recurrent pericarditis, which could lead to increased adoption and revenue.
Bear case
Despite the positive movement, Cardiol's lack of profitability and high market volatility could pose risks for investors. The absence of dividends and a P/E ratio might also deter those who prefer safer investments.
Recent Developments Boost Investor Confidence
The recent publication of Cardiol Therapeutics' Phase II MAvERIC study results in the Journal of the American Heart Association likely contributed to the stock's surge. The study showed that CardiolRx™ effectively alleviates pain and inflammation associated with recurrent pericarditis, a condition affecting many patients. This positive news could lead to increased investor interest and potential partnerships in the healthcare sector.
Market Reaction and Future Outlook
The market's reaction to Cardiol's stock performance indicates strong belief in the company's future potential. Investors are closely watching the developments in their clinical trials, as successful outcomes could lead to significant advancements in treatment options. However, potential investors should remain cautious due to the inherent risks associated with biotech stocks, especially those that have yet to achieve profitability. For more insights into Cardiol Therapeutics, visit the CRDL.TO stock page.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
